Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
| Autor: | Ji Hyun Lee, Jimin Choi, Chang-Ki Min, Sung-Soo Park, Jae-Cheol Jo, Yoo Jin Lee, Jin Seok Kim, Hyeon-Seok Eom, Jongheon Jung, Joon Ho Moon, Hee Jeong Cho, Myung-won Lee, Sung-Soo Yoon, Ja Min Byun, Jae Hoon Lee, Je-Jung Lee, Sung-Hoon Jung, Ho-Jin Shin, Do Young Kim, Jun Ho Yi, Seung-Shin Lee, Young Rok Do, Dok Hyun Yoon, Hyungwoo Cho, Won Sik Lee, Ho Sup Lee, Jieun Uhm, Hyo Jung Kim, Hee Ryeong Jang, Sung-Hyun Kim, Kihyun Kim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Haematologica, Vol 999, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 0390-6078 1592-8721 |
| DOI: | 10.3324/haematol.2024.285534 |
| Popis: | Carfilzomib, lenalidomide, and dexamethasone (KRd) combination therapy improves the survival of patients with relapsed and/or refractory multiple myeloma (RRMM). Nonetheless, evidence on the use of KRd in Asian populations remains scarce. Accordingly, this study aimed at investigating this regimen’s efficacy in a large group of patients. This retrospective study included patients with RRMM who were treated with KRd at 21 centers between February 2018 and October 2020. Overall, 364 patients were included (median age: 63 years). The overall response rate was 90% in responseevaluable patients, including 69% who achieved a very good partial response or deeper responses. With a median follow-up duration of 34.8 months, the median progression-free survival (PFS) was 23.4 months and overall survival (OS) was 59.5 months. Among adverse factors affecting PFS, highrisk cytogenetics, extramedullary disease, and doubling of monoclonal protein within 2 to 3 months prior to start of KRd treatment significantly decreased PFS and overall survival (OS) in multivariate analyses. Patients who underwent post-KRd stem cell transplantation (i.e.delayed transplant) showed prolonged PFS and OS. Grade 3 or higher adverse events (AEs) were observed in 56% of the patients, and non-fatal or fatal AE’s that resulted in discontinuation of KRd were reported in 7% and 2% of patients, respectively. Cardiovascular toxicity was comparable to that reported in the ASPIRE study. In summary, KRd was effective in a large real-world cohort of patients with RRMM with long-term follow-up. These findings may further inform treatment choices in the treatment of patients with RRMM. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|